Polypeptide combination used for tumour immunotherapy, and preparation method therefor
US12270031B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 20, 2020 |
| Grant date | Apr 8, 2025 |
| Priority date | — |
| Expiry date | May 17, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12R2001/385
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a polypeptide combination, a targeting component thereof comprising a shielding peptide, a cleavable part, an antigen-binding part and a first intein fragment, the shielding peptide and the antigen-binding part being connected by means of the cleavable part, and the antigen-binding part being directly or indirectly connected to the first intein fragment; a toxin component thereof comprises a second intein fragment and a toxin, and the second intein fragment is directly or indirectly connected to the toxin; the targeting component and the toxin component form an immunoconjugate by means of the interactive action between the first intein fragment and the second intein fragment; in the immunoconjugate, the shielding peptide and the antigen-binding part are connected by means of the cleavable part, and the antigen-binding part is connected to the toxin. Also provided are a preparation method and a pharmaceutical use for the polypeptide combination.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.